Copanlisib bulk supplier for pharma manufacturers

Copanlisib 60 mg /vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60 mg /vial

Reference Brands: Aliqopa (USA/EU)

Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor used for the treatment of relapsed follicular lymphoma in adults who have received at least two prior systemic therapies. It works by blocking PI3K signaling, which helps slow the growth of cancer cells. The drug is administered as an intravenous infusion using a lyophilized powder formulation (60 mg per vial).

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Copanlisib — third party manufacturing & bulk supply

Copanlisib 60 mg /vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Copanlisib is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Copanlisib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Copanlisib →

Back to Listing

Frequently Asked Questions

Copanlisib is listed as Injection in 60 mg /vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Copanlisib is referenced against Aliqopa (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.